StoryTest
First participant implanted in Newronika's ADVENT pivotal trial of adaptive versus conventional DBS
The first ADVENT participant received the αDBS implant on 21 September 2026 at San Gerardo dei Tintori hospital in Monza, Italy. ADVENT is a randomised, double-blind crossover trial: each patient gets both adaptive and conventional stimulation in random order, and the results are meant to support a US premarket approval application.
- Plans 104 adults with Parkinson's referred for bilateral subthalamic DBS
- Up to 18 sites in the US and EU; US enrolment expected soon
- Principal investigator at Monza: Prof. Giorgio Carrabba